세계의 안과 치료제 시장 예측(-2030년) : 분자별, 모달리티별, 적응증별, 투여 경로별, 최종사용자별, 지역별

The ophthalmology drugs market is expected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period. The growth of the ophthalmology drugs market has primarily been driven by the increasing prevalence of age-related eye diseases and the availability of several key therapies that address these conditions. Additionally, a robust pipeline of new drugs across various treatment modalities contributes to this growth. Opportunities for geographic expansion in emerging economies, such as Asia Pacific, Latin America, the Middle East, and Africa, also support the market's development.

The monoclonal antibodies & fusion proteins segment is expected to grow at the highest CAGR during the study period.

Monoclonal antibodies (mAbs) & fusion proteins are anticipated to experience the highest growth rate due to unmet needs in treating retinal diseases, advancements in drug delivery, and recent product approvals. The introduction of biosimilars and upcoming products, such as KSI-301, is expected to enhance competition and reduce costs. Key players in this market, including Regeneron and Roche, are vital for growth, while factors like payor acceptance and technological innovations significantly influence market dynamics.

In addition, emerging markets are increasingly adopting these treatments, benefiting from better access and more affordable pricing, particularly with biosimilars. Less frequent dosing further enhances the cost-effectiveness of these therapies. Innovations such as sustained-release implants and gene therapies are also contributing to growth in this sector. Overall, biosimilars are expanding supply and increasing treatment volume.

The US is expected to grow at the highest CAGR in the global ophthalmology drugs market from 2025 to 2030.

The US is expected to experience the highest CAGR in the global ophthalmology drugs market between 2025 and 2035. This rapid growth is primarily driven by an aging population and the high prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME). Additionally, there are significant unmet medical needs, recent drug approvals like Syfovre and Izervay, and a promising pipeline for gene and cell therapies. The US also benefits from a strong research and development ecosystem, efficient FDA approval processes, and robust investment. Furthermore, a favorable reimbursement environment, Medicare coverage, and a willingness to adopt expensive therapies contribute significantly to this growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Key Companies Profiled in the Report:

F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron, Pharmaceuticals Inc. (US), Bayer AG (Germany), AbbVie (US), Novartis AG (Switzerland), Bausch + Lomb (US), Apellis Pharmaceuticals (US), Biogen (US), Astellas Pharma Inc. (US), and Formycon AG (Germany), among others.

Research Coverage:

This research report categorizes the ophthalmology drugs market by molecule (aflibercept, faricimab, ranibizumab, and other molecules), modality (monoclonal antibodies & fusion proteins, small molecules, and other modalities), indication (age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and other indications), route of administration (intravitreal, topical, and other routes of administration), end user (hospitals, long-term care facilities, and specialty centers) and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the ophthalmology drugs market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the ophthalmology drugs market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the ophthalmology drugs market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (aging population and growing prevalence of vision disorders, strong drug pipeline and growing innovation efforts, increasing investments and strategic collaborations, and improved reimbursement policies), restraints (off-label drug use for various indications), opportunities (shifting focus on new drug modalities, expansion into emerging markets, and high unmet needs), and challenges (frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment).
• Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the ophthalmology drugs market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ophthalmology drugs market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the ophthalmology drugs market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Product revenue analysis (bottom-up approach)
    • 2.2.1.2 Revenue share analysis of Regeneron Pharmaceuticals, Inc.
    • 2.2.1.3 MnM repository analysis
    • 2.2.1.4 Primary interviews
  • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 OPHTHALMOLOGY DRUGS MARKET OVERVIEW
• 4.2 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE
• 4.3 OPHTHALMOLOGY DRUGS MARKET SHARE, BY END USER, 2024
• 4.4 OPHTHALMOLOGY DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Aging population and growing prevalence of vision disorders
    • 5.2.1.2 Strong drug pipeline and growing innovation efforts
    • 5.2.1.3 Increasing investments and strategic collaborations
    • 5.2.1.4 Improved reimbursement policies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Off-label drug use for various indications
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Shifting focus on new drug modalities
    • 5.2.3.2 Expansion into emerging markets
    • 5.2.3.3 High unmet needs
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Hybridoma technology
    • 5.3.1.2 Recombinant DNA technology
    • 5.3.1.3 Antibody engineering
    • 5.3.1.4 Gene therapy
    • 5.3.1.5 Nanoformulations
  • 5.3.2 ADJACENT TECHNOLOGIES
    • 5.3.2.1 Optogenetic technology
    • 5.3.2.2 Drug-release technologies
    • 5.3.2.3 Ocular implant technologies
  • 5.3.3 COMPLEMENTARY TECHNOLOGIES
    • 5.3.3.1 3D printing and bioprinting
    • 5.3.3.2 Ocular imaging technologies
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
  • 5.5.2 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
  • 5.5.3 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS
  • 5.7.2 OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
  • 5.7.3 OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS
  • 5.7.4 OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES
• 5.8 PATENT ANALYSIS
• 5.9 REGULATORY ANALYSIS
  • 5.9.1 REGULATORY LANDSCAPE
    • 5.9.1.1 US
    • 5.9.1.2 Europe
    • 5.9.1.3 Emerging markets
  • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10.2 BARGAINING POWER OF SUPPLIERS
  • 5.10.3 BARGAINING POWER OF BUYERS
  • 5.10.4 THREAT OF SUBSTITUTES
  • 5.10.5 THREAT OF NEW ENTRANTS
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 REIMBURSEMENT SCENARIO
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS
• 5.14 INVESTMENT & FUNDING SCENARIO
• 5.15 PIPELINE ANALYSIS
• 5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET
  • 5.16.1 CHALLENGES IN DRUG DISCOVERY
  • 5.16.2 IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS
• 5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET
  • 5.17.1 KEY TARIFF RATES
  • 5.17.2 PRICE IMPACT ANALYSIS
  • 5.17.3 KEY IMPACT ON VARIOUS REGIONS
    • 5.17.3.1 US
    • 5.17.3.2 Europe
    • 5.17.3.3 APAC
  • 5.17.4 MANUFACTURING INDUSTRY IMPACT
    • 5.17.4.1 Ophthalmology drug manufacturers

6 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE

• 6.1 INTRODUCTION
• 6.2 AFLIBERCEPT
  • 6.2.1 HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH
• 6.3 FARICIMAB
  • 6.3.1 GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH
• 6.4 RANIBIZUMAB
  • 6.4.1 CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION
• 6.5 OTHER MOLECULES

7 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY

• 7.1 INTRODUCTION
• 7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS
  • 7.2.1 GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET
• 7.3 SMALL MOLECULES
  • 7.3.1 INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET
• 7.4 OTHER MODALITIES

8 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION

• 8.1 INTRODUCTION
• 8.2 AGE-RELATED MACULAR DEGENERATION
  • 8.2.1 WET AGE-RELATED MACULAR DEGENERATION
    • 8.2.1.1 Increasing demand for effective therapies to drive market
  • 8.2.2 DRY AGE-RELATED MACULAR DEGENERATION
    • 8.2.2.1 Large market opportunity for innovation to drive growth
• 8.3 DIABETIC RETINOPATHY (DR)
  • 8.3.1 FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES
• 8.4 DIABETIC MACULAR EDEMA (DME)
  • 8.4.1 GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME TO DRIVE MARKET
• 8.5 OTHER INDICATIONS

9 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 9.1 INTRODUCTION
• 9.2 INTRAVITREAL
  • 9.2.1 HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET
• 9.3 TOPICAL
  • 9.3.1 EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS
• 9.4 OTHER ROUTES OF ADMINISTRATION

10 OPHTHALMOLOGY DRUGS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
• 10.4 SPECIALTY CENTERS
  • 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH

11 OPHTHALMOLOGY DRUGS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising investments in healthcare research and development to support growth
  • 11.2.3 CANADA
    • 11.2.3.1 Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising focus on clinical research to drive market
  • 11.3.3 UK
    • 11.3.3.1 Ongoing advancements in technology to drive market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing investments and government support to drive market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Growing investments and research to support market
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing geriatric population to drive market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Large diabetic population to boost market
  • 11.4.3 JAPAN
    • 11.4.3.1 Growing aging population to intensify demand for effective treatments
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing diabetic cases, government support, and growing availability of biosimilars to support market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Strong biopharmaceutical sector to drive market growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Strong R&D pipeline and increasing focus on research to support growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Significant rates of visual impairment in region to drive demand for advanced treatments
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing research initiatives and innovations to support market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Growing research initiatives and improving healthcare infrastructure to support growth
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Molecule footprint
    • 12.5.5.4 Modality footprint
    • 12.5.5.5 Indication footprint
• 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 VALUATION OF KEY PLAYERS
  • 12.7.2 FINANCIAL METRICS OF KEY PLAYERS
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 REGENERON PHARMACEUTICALS INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches & approvals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 BAYER AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 NOVARTIS AG
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product approvals
      • 13.1.4.3.2 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 ABBVIE
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
  • 13.1.6 APELLIS PHARMACEUTICALS
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 BIOGEN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches & approvals
  • 13.1.8 BAUSCH + LOMB
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches & approvals
  • 13.1.9 ASTELLAS PHARMA INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 FORMYCON AG
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product launches & approvals
      • 13.1.10.3.2 Deals
  • 13.1.11 BIOCON
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 SANDOZ GROUP AG
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 SANTEN PHARMACEUTICAL CO., LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches
  • 13.1.14 INNOVENT
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product approvals
  • 13.1.15 OUTLOOK THERAPEUTICS, INC.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product approvals
      • 13.1.15.3.2 Deals
  • 13.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product approvals
      • 13.1.16.3.2 Deals
• 13.2 OTHER PLAYERS (PIPELINE COMPANIES)
  • 13.2.1 OCULAR THERAPEUTIX, INC.
  • 13.2.2 OPTHEA LIMITED
  • 13.2.3 KODIAK SCIENCES INC.
  • 13.2.4 EYEPOINT PHARMACEUTICALS, INC.
  • 13.2.5 ALVOTECH
  • 13.2.6 CLEARSIDE BIOMEDICAL
  • 13.2.7 SHANGHAI HENLIUS BIOTECH, INC.
  • 13.2.8 ADVERUM BIOTECHNOLOGIES, INC.
  • 13.2.9 REMEGEN
  • 13.2.10 SPARINGVISION

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS